Skip to main content
Veterinary Medicines

Linco-Spectin 100 222 mg/g - 444.7 mg/g Powder for use in drinking water

Authorised
  • Spectinomycin sulfate
  • Lincomycin hydrochloride

Product identification

Medicine name:
Linco-Spectin 100 222 mg/g - 444.7 mg/g Powder for use in drinking water
Linco-Spectin 100, 222/444,7 mg/g κόνις για χορήγηση με πόσιμο νερό για χοίρους και ορνίθια
Active substance:
  • Spectinomycin sulfate
  • Lincomycin hydrochloride
Target species:
  • Pig
  • Chicken
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Spectinomycin sulfate
    575.90
    milligram(s)
    /
    1.00
    gram(s)
  • Lincomycin hydrochloride
    241.90
    milligram(s)
    /
    1.00
    gram(s)
Pharmaceutical form:
  • Powder for use in drinking water
Withdrawal period by route of administration:
  • Oral use
    • Pig
      • Meat and offal
        no withdrawal period
    • Chicken
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01FF52
Authorisation status:
  • Valid
Authorised in:
  • Cyprus
Available in:
  • Cyprus
Package description:
  • Linco-Spectin 100 222 mg/g - 444.7 mg/g pwdr. for drinking water 1.5 kg
  • Linco-Spectin 100 222 mg/g - 444.7 mg/g pwdr. for drinking water 150 g

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Zoetis Hellas S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Veterinary Services, Ministry Of Agriculture, Natural Resources And Environment
Authorisation number:
  • 7850
Date of authorisation status change:
Reference member state:
  • Belgium
Procedure number:
  • BE/V/0029/001
Concerned member states:
  • Austria
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Poland
  • Portugal
  • Slovakia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 4/04/2025
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."